Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Mehr anzeigen
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
– Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 – – IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review...
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of...
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an...
DURHAM, N.C., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1101 | -11.3505154639 | 0.97 | 1.075 | 0.83 | 361069 | 0.92898367 | CS |
| 4 | -0.0201 | -2.28409090909 | 0.88 | 1.12 | 0.83 | 279922 | 0.94957783 | CS |
| 12 | -0.1301 | -13.1414141414 | 0.99 | 1.12 | 0.8 | 201996 | 0.9206902 | CS |
| 26 | -0.1389 | -13.9066880256 | 0.9988 | 1.19 | 0.75 | 343093 | 0.95226506 | CS |
| 52 | -0.1001 | -10.4270833333 | 0.96 | 1.3 | 0.75 | 354670 | 0.98401173 | CS |
| 156 | -5.5501 | -86.5850234009 | 6.41 | 7.42 | 0.75 | 1272047 | 2.31433479 | CS |
| 260 | -1.0001 | -53.7688172043 | 1.86 | 11.5696 | 0.75 | 1064548 | 3.26782911 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
